Vasopressin, cortisol, and catecholamine concentrations in dogs with dilated cardiomyopathy

American Journal of Veterinary Research

Volumn 66, Issue 10, 2005, Pages 1709-1717

  Tidholm, Anna ^a   Häggström, Jens ^b   Hansson, Kerstin ^b  

^a AniCura Albano Animal Hospital and AniCura Gärdets Animal Clinic   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CREATININE; DOPAMINE; HYDROCORTISONE; NORADRENALIN; VASOPRESSIN; VASOPRESSIN ANTAGONIST;

ADRENALIN URINE LEVEL; ARTICLE; BLOOD SAMPLING; CATECHOLAMINE URINE LEVEL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE URINE LEVEL; DOG DISEASE; DOPAMINE URINE LEVEL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; NEUROENDOCRINOLOGY; NONHUMAN; PHYSICAL EXAMINATION; THORAX RADIOGRAPHY; URINALYSIS; URINARY EXCRETION; VASOPRESSIN BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; CARDIOMYOPATHY, DILATED; CATECHOLAMINES; CREATINE; DOG DISEASES; DOGS; ELECTROCARDIOGRAPHY; HYDROCORTISONE; NOREPINEPHRINE; RADIOGRAPHY, THORACIC; VASOPRESSINS;

ANIMALIA; CANIS FAMILIARIS;

EID: 27844531149     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.1709     Document Type: Article

References (68)

1. Keene BW, Canine cardiomyopathy. In: Kirk RW, ed. Current veterinary therapy X. Small animal practice. Philadelphia: WB Saunders Co, 1989;240-251.
2. Sisson D, O'Grady MR, Calvert CA. Myocardial diseases of dogs. In: Fox PR, Sisson D, Moise NS, eds. Textbook of canine and feline cardiology: principles and clinical practice. Philadelphia: WB Saunders Co, 1999;581-619.
3. Tidholm A, Jönsson L. A retrospective study of canine dilated cardiomyopathy (189 cases). J Am Anim Hosp Assoc 1997; 33:544-550.
4. Thomas WP. Myocardial diseases of the dog. In: Bonagura JD, ed. Contemporary issues in small animal practice: cardiology. New York: Churchill Livingstone Inc, 1987;117-141.
5. Koch J, Pedersen HD, Jensen AL, et al. Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy. Res Vet Med 1995;59:172-175.
6. Vaisanen M, Raekallio M, Kuusela E, et al. Evaluation of the perioperative stress response in dogs administered medetomidine or acepromazine as part of the preanesthetic medication. Am J Vet Res 2002;63:969-975.
7. Noble RE. Diagnosis of stress. Metabolism 2002;51:37-39.
8. Hydbring-Sandberg E, von Walter LW, Höglund K, et al. Physiological reactions to fear provocation in dogs. J Endocrinol 2004;180:439-448.
9. Nicholls DP, Onuoha GN, McDowell G, et al. Neuroendocrine changes in chronic cardiac failure. Basic Res Cardiol 1996;91:13-20.
10. Mitrovic V, Thormann J, Kornecki P, et al. The vasopressor system in patients with heart failure due to idiopathic dilated cardiomyopathy - influence of the clinical stage of disease and of chronic drug treatment. Cardiovasc Drugs Ther 1989;3:771-778.
11. Redfield MM, Aarhus LL, Wright RS, et al. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation 1993;87:2016-2022.
12. Holmer SR, Riegger AJ, Notheis WF, et al. Hemodynamic changes and renal plasma flow in early heart failure: implications for renin, aldosterone, norepinephrine, atrial natriuretic peptide and prostacyclin. Basic Res Cardiol 1987;82:101-108.
13. Francis GS, Cohn JN. The autonomic nervous system in congestive heart failure. Annu Rev Med 1986;37:235-247.
14. Borgarelli M, Tarducci A, Tidholm A, et al. Canine idiopathic dilated cardiomyopathy Part II: pathophysiology and therapy Vet J 2001;162:182-185.
15. Borgarelli M, Badino P, Bergamasco L, et al. Lymphocyte beta-adrenoceptor downregulation in Great Danes with occult dilated cardiomyopathy (DCM) and with DCM and heart failure. Vet J 1999;158:128-134.
16. Tidholm A, Häggström J, Hansson K. Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs. Am J Vet Res 2001;62:961-967.
17. Moise N. Echocardiography. In: Fox PR, ed. Canine and feline cardiology. New York: Churchill Livingstone Inc, 1988;113-156.
18. Sahn DJ, De Maria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
19. Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. J Vet Intern Med 1993;7:247-252.
20. Kienle RD. Echocardiography. In: Kittleson MD, Kienle RD, eds. Small animal cardiovascular medicine. St Louis: CV Mosby Co, 1998;104-105.
21. Cornell CC, Kittleson MD, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311-321.
22. Suter PF, Lord PF. Thoracic radiography, textatlas of thoracic diseases of the dog and cat. Wettswil, Switzerland: Selbstverlag PF Suter, 1984;24-43, 100-113, 480-497, 551-575.
23. Tilley LP. Principles of electrocardiographic recording. Analysis of canine P-QRS-T deflections. Essentials of canine and feline electrocardiography. 2nd ed. Philadelphia: Lea & Febiger, 1985;21-37, 57-97.
24. Kley HK, Schlaghecke R, Kruskemper HL. Stability of steroids in plasma over a 10-year period. J Clin Chem Clin Biochem 1985;23:875-878.
25. Hankeova A. Stability of synthetic vasopressin and oxytocin during different conditions of storage [in Czech]. Cesk Farm 1970;19:57-59.
26. Pliska V, Meyer-Grass M, Bersinger N, et al. Long term stability of lysine vasopressin and of specifically tritiated lysine vasopressin in weakly acidic aqueous solutions. Experientia 1980;36:1145-1146.
27. Boomsma F, Alberts G, van Eijk L, et al. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin Chem 1993;39:2503-2508.
28. Eriksson B-M, Gustafsson S, Person B-A. Determination of catecholamines in urine by ion-exchange liquid chromatography with electrochemical detection. J Chromatogr 1983;278:255-263.
29. Fabiny DL, Ertinghausen G. Automated reaction-rate method for determination of serum creatinine with the Centrichem. Clin Chem 1971;17:676-700.
30. Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 1968;32:745-759.
31. Goldsmith SR, Francis GS, Cowley AW, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1:1385-1390.
32. Riegger GA, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 1982;72:49-52.
33. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-1729.
34. McKinley MJ, Mathai ML, McAllen RM, et al. Vasopressin secretion: osmotic and hormonal regulation by the lamina terminalis. J Neuroendocrinol 2004;16:340-370.
35. Trasher TN, Keil LC. Systolic pressure predicts plasma vasopressin responses to hemorrhage and vena caval constriction in dogs. Am J Physiol Regul Integr Comp Physiol 2000;279:R1035-R1042.
36. Trasher TN. Baroreceptor regulation of vasopressin and renin secretion: low-pressure versus high-pressure receptors. Front Neuroendocrinol 1994;15:157-196.
37. Nakamura Y, Haneda T, Osaki J, et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin VIA receptor. Eur J Pharmacol 2000;391:39-48.
38. Hupf H, Grimm D, Riegger GA, et al. Evidence for a vasopressin system in the rat heart. Circ Res 1999;84:356-370.
39. Goldsmith MD. Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail 2002;8:251-256.
40. Burger AJ, Burger MR, Aronson D. New therapies for the treatment of congestive heart failure. Drugs Today 2002;38:31-48.
41. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:H2245-H2254.
42. Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 2000;85:1834-1840.
43. Noirhomme P, Luc J, Underwood M, et al. The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Eur J Cardiothorac Surg 1999;16:63-67.
44. Häggström J, Hansson K, Kvart C, et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentrations in dogs. Am J Vet Res 1997;58:77-82.
45. van Vonderen IK, Wolfswinkel J, Oosterlaken-Dijksterhuis MA, et al. Pulsatile secretion pattern of vasopressin under basal conditions, after water deprivation, and during osmostimulation in dogs. Domest Anim Endocrinol 2004;27:1-12.
46. Engeland WC, Byrnes GJ, Gann DS. The pituitary-adreno-cortical response to hemorrhage depends on the time of day. Endocrinology 1982;110:1856-1860.
47. Palazzolo DL, Quadri SK. The effects of aging on the circadian rhythm of serum cortisol in the dog. Exp Gerontol 1987;22:379-387.
48. Gordon CR, Lavie P. Day-night variations in urine excretions and hormones in dogs: role of autonomic innervation. Physiol Behav 1985;35:175-181.
49. Benton LA, Yates FE. Ultradian adrenocortical and circulatory oscillations in conscious dogs. Am J Physiol 1990;258:R578-R590.
50. van Vonderen IK, Kooistra HS, Rinjberk A. Influence of veterinary care on the urinary corticoid:creatinine ratio in dogs. J Vet Intern Med 1998;12:431-435.
51. Lenders JW, Pacak K, Eisenhofer G. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann N Y Acad Sci 2002;970:29-40.
52. Swedberg K, Viquerat C, Rouleau JL, et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984; 54:783-786.
53. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41:39-52.
54. 1 receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
55. Bristow MR, Kantrowitz NE, Ginsburg R, et al. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 1985;17:41-52.
56. Ware WA, Lund DD, Subieta AR, et al. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990;197:1475-1480.
57. Cannon WB. Bodily changes in pain, hunger, fear and rage. Boston: Branford, 1929.
58. Viquerat CE, Daly P, Swedberg K, et al. Endogenous catecholamine levels in chronic heart failure. Am J Med 1985;78:455-460.
59. Francis GS, Goldsmith SR, Pierpont G, et al. Free and conjugated plasma catecholamines in patients with congestive heart failure. J Lab Clin Med 1984;103:393-398.
60. Petch MC, Nayler WG. Uptake of catecholamines by human cardiac muscle in vitro. Br Heart J 1979;41:336-339.
61. Kurose M, Okumura K, Ogawa H, et al. Reduced cardiac extraction of norepinephrine and epinephrine in patients with heart failure - correlation with left ventricular function. Int J Cardiol 1994;47:21-29.
62. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-211.
63. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
64. Waagstein F, Hjalmarson Å, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
65. Heidenreich PA, Lee TT, Massie BM. Effects of beta blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
66. Lokhandwala MF, Jandhyala BS. The role of sympathetic nervous system in the vascular actions of dopamine. J Pharmacol Exp Ther 1979;210:120-126.
67. Robie NW, Goldberg LI. Comparative systemic and regional hemodynamic effect of dopamine and dobutamine. Am Heart J 1975;90:340-345.
68. Clark BJ. The role of dopamine in the periphery. In: Fluckiger ME, Thorner MO, eds. The dopaminergic system. Heidelberg, Germany: Springer Sandoz, 1985;27-39.